A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Juvenile rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Acronyms GO-VIVA
- Sponsors Janssen Research & Development
- 06 Aug 2018 Planned primary completion date changed from 28 Jun 2018 to 21 Feb 2023.
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Mar 2017 Planned End Date changed from 1 Oct 2022 to 21 Feb 2023.